NY-FUNDGUARD
FundGuard, the industry’s first fully cloud-native, AI-powered, multi-asset class investment accounting platform for asset managers, asset owners, custodian banks and fund administrators today announced the successful closure of its Series C funding round, amounting to $100 million. This latest round of investment - led by Key1 Capital and new investors including Euclidean Capital and funds managed by Hamilton Lane (Nasdaq: HLNE) - marks another significant milestone on FundGuard’s path towards becoming the industry’s new era investment accounting utility.
The round also saw strong participation from existing strategic investors, plus the company’s earliest financial investors: Blumberg Capital and Team8.
Founded in 2018, FundGuard is transforming investment operations by leveraging cloud-native technology and AI capabilities to modernize and streamline investment accounting operations and workflows. Key to the company’s success has been the combined expertise of its leadership, including experienced funds industry executives and enterprise cloud technology and data science innovators. Backed by some of the world’s leading financial institutions and now with a total investment of over $150 million to date, this round follows two years of evolution and expansion, including new client acquisition, customer onboarding, significant hiring of top talent across Customer Success, R&D, Product Management and Sales, and the opening of the company’s Boston, London and Toronto offices.
“FundGuard is shaping the future of investment and fund accounting,” said Lior Yogev, CEO and Co-Founder, FundGuard. “This latest significant investment round reflects the ongoing support of the industry, the confidence our investors have in the value our products bring to the market, and their trust in our leadership and strategic roadmap.”
“The exceptional team at FundGuard has developed a unique, cutting-edge technology platform over the last five years, empowering asset managers and fund administrators with a timely, accurate, and cost-efficient solution to support their investment accounting operations,” said Amit Pilowsky, Co-Founder and Managing Partner, Key1 Capital. “It is rare to witness a company at this stage receiving significant attention from the largest and most sophisticated clients in an industry dominated by incumbents. This serves as a testament to just how valuable and unique FundGuard’s solution is. FundGuard is just scratching the surface of its potential to revolutionize the Investment Management industry, and we are honored to be their partner.”
The funds raised in this round will be strategically deployed by FundGuard for ongoing investment in product innovation and continued onboarding of existing and new customers.
“We are thrilled to partner with our newest investors,” said John Lehner, President, FundGuard. “With their support and partnership, and the continued dedication of our existing investors and talented team, FundGuard is poised for continued growth and market expansion.”
About FundGuard
FundGuard is a cloud-native SaaS platform for investment management and administration that is powered by AI. FundGuard helps asset managers and their service providers to manage mutual funds, ETFs, hedge funds, insurance products, and pension funds, supporting digital transformation, operations automation, AI-based insights, resiliency, and migration to the cloud. FundGuard is backed by strategic partners including Citi and State Street, and investment firms Blumberg Capital, Key1 Capital, LionBird Ventures, and Team8 among others.
Please visit www.fundguard.com
About Key1 Capital
Key1 Capital is a growth-stage VC fund backing Israeli and European companies. With two decades of experience in leadership roles at Goldman Sachs, the team has played a key role in the growth of top-tier technology companies scaling globally. Key1 actively seeks to partner with visionary founders who think big and are driven by strong values, helping them meaningfully expand through ultimate exit.
Please visit: www.key1capital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325557613/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cirium Enhances Industry-Leading On-Time Performance Advisory Board with Three Esteemed Aviation Leaders4.12.2024 12:12:00 CET | Press release
Cirium, the world’s most trusted source of aviation analytics, has appointed three prominent aviation experts to its Airline and Airport On-Time Performance Advisory Board. The move underscores Cirium’s commitment to maintaining its position as the global gold standard for airline and airport performance analytics. As the first and only company to establish an On-Time Performance Advisory Board, Cirium ensures an unbiased, data-driven view of operational excellence. The latest appointments—Eamonn Brennan, Scott McCartney, and Alex de Gunten—bring over 75 years of combined experience, enhancing the board’s mission to uphold Cirium’s reputation as the industry benchmark. Jeremy Bowen, Cirium CEO, said “Adding Eamonn, Scott, and Alex to our Advisory Board is a confirmation of our unwavering commitment to operational reliability and excellence. Their unique perspectives, spanning safety, operations, performance, journalism, and global airline strategy, will amplify our ability to provide i
Delta-Fly Pharma Inc.: Update for Development Status of DFP-177294.12.2024 12:00:00 CET | Press release
We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. We had presented these results at the ESMO Gastrointestinal Cancers Co
OPEX® Falcon+® RED™ Scanners Named High Volume Imaging Product of the Year4.12.2024 10:00:00 CET | Press release
Falcon+ RED’s Unique One-Touch Mail Extraction and Document Scanning Offers Clients Efficient, Accurate, Secure Document Processing OPEX® Corporation, a global leader in Next Generation Automation providing solutions for document, mail, and warehouse automation, has received an industry award for the company’s Falcon+® RED™ line of innovative scanners that consolidate manual prep steps into one streamlined one-touch process. Falcon+ RED was named the winner in the Imaging Product of the Year: High Volume category during the Document Manager magazine DM Awards held in London in November. DM Award product and company winners are voted for by readers of DM magazine and include industry peers and executives. “We are honored to receive this prestigious award,” said Scott Maurer, President, OPEX International. “Clients across the globe look to unique solutions like Falcon+ RED to maximize their mailroom efficiency with unparalleled scanning accuracy and secure data management.” OPEX Falcon+
Hyatt to Advance Leadership Role in Luxury and Lifestyle With Over 50 Hotel Openings Planned in Next Two Years4.12.2024 09:00:00 CET | Press release
Hyatt spotlights ambitious growth strategy in luxury and lifestyle segments, with more focused brand portfolios to unlock the full potential of each brand. Hyatt Hotels Corporation (NYSE: H) today showcased during ILTM Cannes, the world’s leading luxury travel trade show, an impressive pipeline of over 50 luxury and lifestyle hotels set to open worldwide by 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204645922/en/ Park Hyatt London River Thames (Photo: Business Wire) Luxury travel demand surged in 2023 and continues to rise and with Savills forecasting a 52.8% increase in Europe’s existing luxury hotel stock by 2028, highlighting strong investor confidence in the segment’s long-term growth potential. With 70% of Hyatt’s global rooms categorized as luxury and upper upscale and Hyatt having expanded this portfolio by an impressive 28 luxury hotels and resorts in the past three years and doubled its luxury room coun
LTIMindtree Announces Partnership and Strategic Investment in Voicing.AI, An Agentic AI Solution for Customer Engagement Processes4.12.2024 05:00:00 CET | Press release
LTIMindtree USA Inc., a wholly owned subsidiary of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced a partnership, including a strategic investment in Voicing.AI, a next-generation start-up. This partnership aligns with LTIMindtree’s strategy, AI in everything, Everything for AI and AI for Everyone. Voicing.AI’s proprietary technology brings human-like voice capability across more than 20 languages with conversational, contextual, and emotional intelligence, in what is typically referred to as ‘agentic AI’. LTIMindtree aims to reshape the future of Business Processes by leveraging AI-led platforms. This will enable their clients to optimize costs, reduce risk, enhance user experience, address revenue leakages, and enhance upsell opportunities. LTIMindtree will help clients integrate Voicing.AI with their custom tools, knowledge bases - both structured or unstructured, CRM systems, and leading call management platforms and sys
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom